Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesCoffee consumption and risk of lung cancer: A meta-analysis
Lung Cancer, 05/13/09
Tang N et al. - To clarify the role of coffee in lung cancer, it was reported that high or an increased consumption of coffee may increase the risk of lung cancer. Because the residual confounding effects of smoking or other factors may still exist, these results should be interpreted with caution.
Methods- PubMed and EMBASE databases were searched (from 1966 to January 2009) and the reference lists of retrieved articles.
- Study-specific risk estimates were pooled using random-effects model.
- 5 prospective studies and 8 case–control studies involving 5347 lung cancer cases and 104,911 non-cases were included.
- Combined results indicated a significant positive association between highest coffee intake and lung cancer.
- An increase in coffee consumption of 2 cups/day was associated with a 14% increased risk of developing lung cancer.
- In stratified analyses, highest coffee consumption was significantly associated with increased risk of lung cancer in prospective studies, but borderline significantly associated with decreased risk of lung cancer in non-smokers.
- Decaffeinated coffee drinking was associated with decreased lung cancer risk, although the number of studies on this topic was relatively small.
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Sponsor
Article Search
Sponsor